GLP-1 pills in Australia: what is registered, and what is still waiting.

Rybelsus is oral semaglutide, a GLP-1 receptor agonist tablet registered in Australia for adults with type 2 diabetes. It is not approved for weight loss.

The TGA registered Rybelsus for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise. It can be used on its own when metformin is inappropriate, or in combination with other diabetes medicines. The TGA decision was made on 4 February 2022 and the ARTG entry followed on 7 February 2022. The tablets come in three strengths: 3, 7 and 14 mg. The TGA's public assessment report (AusPAR), published 27 October 2022, sets out the evidence behind the decision.

Semaglutide is the same active ingredient as in Ozempic and Wegovy, which are injections. Sharing an ingredient does not make the products interchangeable: each has its own registered uses, doses and instructions. Questions about which form suits a particular person belong with their doctor or pharmacist.

On cost, healthdirect's PBS data dated 3 August 2026 state that Rybelsus "is not listed on the Pharmaceutical Benefits Scheme". By contrast, Ozempic remains PBS-listed for type 2 diabetes. Listings can change, so the current PBS Schedule or a pharmacist is the place to confirm.

The Wegovy pill is a 25 mg oral semaglutide tablet for weight management. It is approved in the US but is not registered in Australia.

Novo Nordisk announced US approval on 22 December 2025, describing it as the first oral GLP-1 for weight management. In Australia, the healthdirect listing of Wegovy, which draws on ARTG data updated 3 August 2026, shows injectable presentations only. No Australian timing for the tablet has been confirmed.

In Australia, Wegovy is a once-weekly injection. Its CMI lists weight management in adults and adolescents, reducing the risk of heart-disease events in some adults with a history of heart disease, and a provisional approval for a liver condition (MASH) with moderate-to-advanced fibrosis. Wegovy is not PBS-listed as of October 2026; the Wegovy and the PBS explainer covers its PBS status.

The Wegovy pill and Rybelsus are both oral semaglutide, but they are different products: the Wegovy pill is a 25 mg tablet for weight management in the US, while Rybelsus comes in 3, 7 and 14 mg tablets for type 2 diabetes.

The main differences are how often they are taken, what kind of molecule they are, and, in Australia, what they are registered for.

• Frequency. Orforglipron is taken once daily. Wegovy and Mounjaro, the injections registered in Australia for weight management, are given once a week.
• Molecule. Rybelsus and the Wegovy pill contain semaglutide, the same active ingredient as the Ozempic and Wegovy injections. Orforglipron is a different, non-peptide small molecule. Mounjaro (tirzepatide) acts on two receptors, GIP and GLP-1; see how Mounjaro works.
• Registered uses. In Australia, the only registered oral option covered here, Rybelsus, is for type 2 diabetes. Medicines registered for weight management, such as Wegovy and Mounjaro, are injections.
• Cost and subsidy. Neither Rybelsus, Wegovy nor Mounjaro is PBS-listed, according to the latest sources reviewed; Ozempic remains PBS-listed for type 2 diabetes. The Mounjaro and the PBS explainer has the detail for tirzepatide.

Whether a tablet or an injection suits someone, if either, is a clinical decision. The weight-loss medication in Australia guide and GLP-1 medicines in Australia describe the registered options without recommending any of them.

Products that are not on the ARTG have not been evaluated by the TGA, and some have turned out to contain something other than what the label says.

In September 2026 the TGA tested a vial sold online as retatrutide, an unapproved investigational medicine, after a person was hospitalised with uncontrollable vomiting and a torn oesophagus. It contained no retatrutide, only undeclared semaglutide at about 8 times the level in registered semaglutide products. The TGA also warns that imported products identified only by codes, or without a clear active ingredient and strength, will not be released under the Personal Importation Scheme and may be seized and destroyed.

Orforglipron and the Wegovy pill are not registered in Australia, so neither is available here as a registered product. The retatrutide in Australia guide explains the TGA's wider warnings on unapproved peptide products.